Drugs / BMS-914392
Trials 2 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT01211821 | Sep → Nov 2010 | atrial fibrillation | Bristol-Myers Squibb | Completed | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT01356914 | May 2011 → Jun 2012 | atrial fibrillation | Bristol-Myers Squibb | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | BMS 914392 | “BMS 914392 is a potent, selective, oral inhibitor of the IKACh current” PMID 26462707 ↗ Oct 2015 |
| Action | Inhibit | “BMS 914392 is a potent, selective, oral inhibitor of the IKACh current” PMID 26462707 ↗ Oct 2015 |
| Route | Oral | “Tablets, Oral” NCT01211821 ↗ |